Products |

Fortitude bioresorbable stent (BRS)

Related Content

Novel bioresorbable scaffold system being developed for expanded indications
News | Stents Bioresorbable
AI Measures Fat Around the Heart, a Key to Predicting Heart Attacks

February 14, 2024 — Efemoral Medical, developer of advanced interventional bioresorbable therapies, today announced that ...

Home February 14, 2024
Home
Abbott's landmark LIFE-BTK randomized clinical trial met its primary safety and effectiveness endpoints, demonstrating that Esprit BTK offers significant advancements in opening and keeping blocked arteries below-the-knee open compared to the standard of care, balloon angioplasty
News | Stents Bioresorbable
Late-breaking Data Show Esprit BTK Drug-eluting Resorbable Scaffold Reduces Chronic Limb-threatening Ischemia Progression Compared to the Standard of Care

October 30, 2023 — Abbott announced late-breaking data from the LIFE-BTK clinical trial evaluating the Esprit BTK ...

Home October 30, 2023
Home
First-in-Human Study Also Showed the Return of Vasomotion in Patients Treated with the DREAMS 3G Scaffold
News | Stents Bioresorbable
BIOMAG-I Study OCT Analysis Confirmed That BIOTRONIK’s Newest Resorbable Magnesium Scaffold Resorbed at 12 Months

September 5, 2023 — New data from the BIOMAG-I first-in-human trial shed light on the vascular healing process following ...

Home September 05, 2023
Home
Six-month results from the BIOMAG-I clinical study including intravascular imaging data were presented at CRT 2023
News | Stents Bioresorbable
New Data Highlight Promising Angiographic and Safety Profile of BIOTRONIK’s Third Generation Resorbable Magnesium Scaffold

March 16, 2023 — Prof. Michael Haude, BIOMAG-I Coordinating Clinical Investigator, presented the latest results of the ...

Home March 16, 2023
Home
Grant Proceeds Will Support Pre-Clinical Studies
News | Stents Bioresorbable
Efemoral Medical Awarded Phase II SBIR Grant from NIH to Advance Treatment for Peripheral Artery Disease

October 11, 2022 — Efemoral Medical, developer of advanced interventional bioresorbable therapies, announced that it has ...

Home October 11, 2022
Home
The multi-center first-in-men study evaluates the safety and performance of the next generation of BIOTRONIK’s Resorbable Magnesium Scaffold (RMS)
News | Stents Bioresorbable
BIOMAG-I Clinical Trial Reaches Primary Endpoint at Six Month for Unique Next Generation Resorbable Magnesium Scaffold

September 28, 2022 — In the "TCT Innovation" session Prof. Michael Haude, BIOMAG-I Coordinating Clinical Investigator ...

Home September 28, 2022
Home
Magmaris Scaffold Performs Well in Real World Settings Even in More Complex Patient Groups
News | Stents Bioresorbable
BIOSOLVE-IV Full-Cohort Two-Year Data Confirm Excellent Safety and Efficacy Profile of Magmaris Resorbable Magnesium Scaffold

September 27, 2022 — BIOTRONIK announced the presentation of new full-cohort 2-year BIOSOLVE-IV data. In a poster ...

Home September 27, 2022
Home
A peripheral artery disease (PAD) patient CT scan showing blockages in the femoral arteries in the legs with collateral flow in the leg on the right.
News | Stents Bioresorbable
First-In-Human Use Reported for Bioresorbable Efemoral Vascular Scaffold System

December 16, 2020 — Efemoral Medical announced the first-in-human (FIH) use of the its Efemoral bioresorbable vascular ...

Home December 16, 2020
Home
Abbott Espirit BTK Bioresorbable stent, or bioresorbable vascular scaffold (BVS) measures 99 microns and is made from poly-L-lactide (PLLA), a semi-crystalline bioresorbable polymer engineered to resist vessel recoil and provide a platform for drug delivery. Abbott Absorb
Feature | Stents Bioresorbable
Abbott Restarts Bioresorbable Stent Clinical Trials With New Esprit Below-the-knee Scaffold

September 3, 2020 — Abbott today announced the start of the LIFE-BTK clinical trial to evaluate the safety and ...

Home September 03, 2020
Home
News | Stents Bioresorbable
Bioresorbable Stent Shows Good 5-Year Outcomes in ABSORB BTK Trial

November 7, 2019 — Although the Abbott Absorb fully bioresorbable drug-eluting stent (DES) was taken off the market due ...

Home November 07, 2019
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now